Stocks · News reference

Liminatus Pharma shares are trading lower. The company announced it has engaged Synex Consulting to support the clinical development of IBC101, CD19xCD22 bivalent CAR-T cell therapy candidate.

Aug 24, 2026, 7:35 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 9:07 PMBenzinga Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-market session. The market value of their outstanding shares is at $40.0 billion. The company's, Q2 earnings came
ALPS BBLG CELU HSCS INTS
BenzingaAug 24, 2026, 12:01 PMBenzinga Newsdesk
Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
LIMN
BenzingaAug 19, 2026, 1:05 PMBenzinga Newsdesk
Liminatus Pharma shares are trading lower after the company announced a reverse stock split of its common stock at a ratio of 1-for-50.
LIMN